NCT01009060 - Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2009

Primary Completion Date

August 10, 2011

Study Completion Date

August 10, 2011

Conditions

Schizophrenia

Interventions

DRUG

GSK239512

Histamine H3 Antagonist

DRUG

Placebo

Placebo to match GSK239512

Trial Locations (15)

10016

GSK Investigational Site, New York

10032

GSK Investigational Site, New York

21228

GSK Investigational Site, Catonsville

27509

GSK Investigational Site, Butner

46222

GSK Investigational Site, Indianapolis

60611

GSK Investigational Site, Chicago

90073

GSK Investigational Site, Los Angeles

90502

GSK Investigational Site, Torrance

91950

GSK Investigational Site, National City

92102

GSK Investigational Site, San Diego

92845

GSK Investigational Site, Garden Grove

95817

GSK Investigational Site, Sacramento

02114

GSK Investigational Site, Boston

02130

GSK Investigational Site, Jamaica Plain

08054

GSK Investigational Site, Mount Laurel